You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

CLINICAL TRIALS PROFILE FOR INVOKANA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Invokana

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01877889 ↗ A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers Completed Janssen-Cilag International NV Phase 1 2013-07-01 The purpose of this study is to compare the pharmacodynamics (ie, how the drug affects the body) of canagliflozin with the pharmacodynamics of dapagliflozin.
NCT01916863 ↗ Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects Completed Lexicon Pharmaceuticals Phase 1 2013-08-01 The purpose of this study is to assess the effect of LX4211 and the comparator drug canagliflozin on intestinal glucose absorption and metabolism after a single dose in healthy subjects in comparison to placebo.
NCT02009488 ↗ Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Completed Janssen Research & Development, LLC Phase 1 2014-09-08 The purpose of this study is to assess changes from baseline in insulin sensitivity, hepatic fat content and beta cell function after approximately 24-25 weeks of treatment with canagliflozin compared to placebo in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic (blood sugar) control on metformin monotherapy or on combination therapy with metformin and a dipeptidyl peptidase-4 (DPP-4) inhibitor.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Invokana

Condition Name

Condition Name for Invokana
Intervention Trials
Diabetes Mellitus, Type 2 6
Type 2 Diabetes 3
Obesity 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Invokana
Intervention Trials
Diabetes Mellitus 12
Diabetes Mellitus, Type 2 11
Heart Failure 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Invokana

Trials by Country

Trials by Country for Invokana
Location Trials
United States 48
United Kingdom 3
Germany 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Invokana
Location Trials
Texas 4
Massachusetts 4
Ohio 3
Florida 3
California 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Invokana

Clinical Trial Phase

Clinical Trial Phase for Invokana
Clinical Trial Phase Trials
Phase 4 10
Phase 3 2
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Invokana
Clinical Trial Phase Trials
Completed 11
Recruiting 4
Active, not recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Invokana

Sponsor Name

Sponsor Name for Invokana
Sponsor Trials
Janssen Scientific Affairs, LLC 7
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 3
Janssen Research & Development, LLC 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Invokana
Sponsor Trials
Other 32
Industry 14
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

INVOKANA: Clinical Trials, Market Analysis, and Projections

Introduction to INVOKANA

INVOKANA (canagliflozin) is a significant medication in the treatment of Type 2 diabetes and its associated complications, particularly diabetic kidney disease (DKD) and cardiovascular events. Developed by Janssen Pharmaceutical Companies of Johnson & Johnson, INVOKANA has been a focal point in both clinical trials and market dynamics.

Clinical Trials Overview

CREDENCE Study

The CREDENCE study was a landmark clinical trial that evaluated the efficacy of INVOKANA in reducing the risk of end-stage kidney disease (ESKD), doubling of serum creatinine (dSCr), or renal or cardiovascular (CV) death in patients with Type 2 diabetes and chronic kidney disease (CKD). The study was stopped early due to the demonstration of significant efficacy, with INVOKANA showing a 30% reduction in the primary composite endpoint compared to placebo[3].

CANVAS and CANVAS-R Studies

The CANVAS and CANVAS-R studies were part of the CANVAS Program, which assessed the cardiovascular outcomes of INVOKANA in patients with Type 2 diabetes and established cardiovascular disease (CVD) or multiple risk factors for CVD. These studies found that INVOKANA reduced the risk of hospitalization for heart failure and the composite of CV death or hospitalization for heart failure[3].

Renal Protective Effects

INVOKANA has been shown to have significant renal protective effects. By inhibiting the SGLT2 protein in the kidneys, which is responsible for glucose reabsorption, INVOKANA reduces the amount of glucose reabsorbed by the kidneys, thereby decreasing the workload on the kidneys and reducing the risk of kidney failure. This mechanism has been highlighted in various studies, including the CREDENCE trial, which demonstrated a reduction in the progression of kidney disease[1][3].

Market Analysis

Market Share and Competition

Despite its clinical successes, INVOKANA has faced challenges in the market. It has lost significant market share to its rival, Jardiance (empagliflozin), developed by Eli Lilly and Boehringer Ingelheim. As of 2017, INVOKANA's market share had declined by 6 percentage points, while Jardiance gained ground, controlling 23% of the market compared to INVOKANA's 45%[5].

Sales Performance

The sales performance of INVOKANA has been impacted by several factors, including increased contracting discounts, higher utilization in Medicaid, and the loss of market share to competitors. In the second quarter of 2017, INVOKANA's sales were $76 million below consensus estimates, reflecting a 20.5% shortfall[5].

Projections and Future Outlook

Market Size and Growth

The diabetic nephropathy market, which includes treatments like INVOKANA, is projected to grow significantly. As of 2023, the market size was valued at USD 9,717.1 million, and it is expected to reach USD 14,572.9 million by 2034. This growth is driven by the increasing utilization of effective medications and the rising prevalence of diabetic kidney disease[2].

New Developments and Competitors

In addition to INVOKANA, other drugs are being developed to address diabetic nephropathy. For example, Inversago Pharma's investigational drug INV-202 is currently in Phase 2 clinical trials, aiming to evaluate its efficacy and safety in patients with DKD. This ongoing research may introduce new therapeutic options and potentially alter the market landscape[2].

Safety Concerns and Regulatory Actions

Amputation Risk

INVOKANA has been associated with an increased risk of leg and foot amputations. Clinical studies, such as the CANVAS and CANVAS-R trials, have shown higher amputation rates in patients treated with INVOKANA compared to those receiving a placebo. This led the FDA to add a boxed warning to the drug's label regarding this risk[4].

Ketoacidosis and Other Side Effects

There have also been reports of ketoacidosis and other serious side effects associated with INVOKANA. Despite these concerns, INVOKANA remains on the market, although its sales have declined due to these safety issues and increased competition[4].

Impact on Patient Care

Diagnosis and Treatment of DKD

The approval of INVOKANA for reducing the risk of ESKD and cardiovascular events in patients with Type 2 diabetes and CKD has significant implications for patient care. Simple tests such as eGFR (estimated glomerular filtration rate) and ACR (albumin-to-creatinine ratio) can diagnose kidney disease and predict cardiovascular risk. The National Kidney Foundation emphasizes the importance of these tests and the need for patients to discuss new treatment options with their healthcare professionals[1].

Key Takeaways

  • Clinical Efficacy: INVOKANA has demonstrated significant efficacy in reducing the risk of kidney failure and cardiovascular events in patients with Type 2 diabetes and CKD.
  • Market Challenges: Despite clinical successes, INVOKANA faces market challenges, including loss of market share to competitors and safety concerns.
  • Future Outlook: The diabetic nephropathy market is projected to grow, with new developments and competitors potentially altering the market landscape.
  • Safety Concerns: INVOKANA is associated with increased risks of amputation and other serious side effects, leading to regulatory actions and warnings.

FAQs

What is INVOKANA used for?

INVOKANA (canagliflozin) is used to treat Type 2 diabetes and reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with chronic kidney disease (CKD).

What are the key findings of the CREDENCE study?

The CREDENCE study showed that INVOKANA reduced the risk of ESKD, doubling of serum creatinine, or renal or cardiovascular death in patients with Type 2 diabetes and CKD by 30% compared to placebo.

Why has INVOKANA's market share declined?

INVOKANA's market share has declined due to increased competition from rival drugs like Jardiance, as well as factors such as contracting discounts and higher Medicaid utilization.

What are the safety concerns associated with INVOKANA?

INVOKANA is associated with an increased risk of leg and foot amputations and other serious side effects such as ketoacidosis.

Is INVOKANA still available on the market?

Yes, INVOKANA is still available on the market, although its sales have declined due to safety concerns and increased competition.

Sources

  1. FDA Approves New Drug to Treat Diabetes-Related Kidney Disease - National Kidney Foundation
  2. Diabetic Nephropathy Market Estimated to Reach USD 14,572.9 Million by 2034 - BioSpace
  3. Heart Failure Outcomes of INVOKANA - Clinical Trials - Janssen Science
  4. Invokana Lawsuits 2025 Update - Lezdo Tech Med
  5. J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances - FiercePharma
Last updated: 2025-01-01

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.